Clinical Trial Detail

NCT ID NCT03634540
Title A Trial of PT2977 in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Peloton Therapeutics, Inc.
Indications

renal cell carcinoma

Therapies

Cabozantinib + PT 2977

Age Groups: adult senior

No variant requirements are available.